Safinamide Mesylate

Description: Safinamide Mesylate (formerly PNU-151774E, FCE-28073; NW-1015; EMD-1195686; Xadago), the mesylate salt of Safinamide, is a selective and reversible inhibitor of MAO-B with anti-PD (Parkinson's diseas) effects. In inhibits MAO-B with an IC50 of 98 nM, and exhibits 5918-fold selectivity for MAO-B over MAO-A. Safinamide mesylate is the 3rd generation reversible MAO-B inhibitor, which also blocks sodium voltage-sensitive channels and modulates stimulated release of glutamate. Safinamide (formerly known as EMD 1195686 and FCE 26743; trade name: Xadago) is an FDA approved drug. As of 2017, Safinamide gained FDA approval to treat Parkinson's disease.

References: Neurology. 2006 Oct 10; 67(7 Suppl 2):S18-23; J Med Chem. 2007 Nov 15; 50(23):5848-52.

Related CAS: 202825-46-5 (mesylate); 133865-89-1 (free base);

Chemical Name: (S)-2-((4-((3-fluorobenzyl)oxy)benzyl)amino)propanamide methanesulfonate

SMILES Code: C[CH](NCC1=CC=C(OCC2=CC=CC(F)=C2)C=C1)C(N)=O.CS(=O)(O)=O